BRIEF-Amgen announces Repatha significantly reduced the risk of cardiovascular events in FOURIER outcomes study
February 02, 2017 at 16:03 PM EST
* Amgen announces Repatha (evolocumab) significantly reduced the risk of cardiovascular events in FOURIER outcomes study
